UPB logo

UPSTREAM BIO INC

UPBNASDAQ
🏆 #3458 by market capEarnings Nov 3US Equity
$5.20▼ $0.12 (−2.26%)
After hours · at close
🔔
Track UPB
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.3%
7d▼ 5.1%
14d▼ 4.8%
30d▼ 22.2%
ytd▼ 80.9%
1y▼ 70.2%
🏦Market Cap
$283M
Small Cap
📈Revenue Growth (YoY)
+20.4%
Healthy
📊Gross Margin
98.5%
High
💵FCF Margin
-4317.4%
Thin
⚖️P/S Ratio
88.6x
Expensive
Otter Score
76
Good

Trading Snapshot

Day Range
$5.16 – $5.28
52-Week Range
$4.99 – $33.68
Volume
$1.89B
Avg Volume
$1.82B
Shares Outstanding
54.4M
Next Earnings
Dec 5, 2026

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
$773,000
P/E Ratio
-1.8
P/S Ratio
88.6x
EPS (TTM)
$-2.87
Dividend Yield
0.00%
Dilution (1yr)
+5.6%

Why Investors Own UPB

  • ✓High-growth profile — revenue up +48.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 75% gross margin and 10% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

UPB logo

UPSTREAM BIO INC

UPB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3M▲ +20.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$160M▲ +106.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$133M▲ +123.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
54.2M▲ +5.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$100M▼ −$224M YoY
StockOtter · stockotter.space

About UPSTREAM BIO INC

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$6.57
▲ +26.3% Upside
High Target$7.42
Low Target$5.44
Based on 33 analysts

Latest News & Updates

🚀
Barron’s·2h ago

UPSTREAM BIO INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift UPB price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

UPSTREAM BIO INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.